

To: Strauss, Linda[Strauss.Linda@epa.gov]; Cleland-Hamnett, Wendy[Cleland-Hamnett.Wendy@epa.gov]; Wise, Louise[Wise.Louise@epa.gov]; Schmit, Ryan[schmit.ryan@epa.gov]; Morris, Jeff[Morris.Jeff@epa.gov]; Pierce, Alison[Pierce.Alison@epa.gov]; Ng, Brian[Ng.Brian@epa.gov]
From: Beck, Nancy
Sent: Tue 5/16/2017 5:11:24 PM
Subject: RE: Pat asking for our good news story - FW: LINDA/: BNA - PAT - Reporter checking status of this request

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

From: Strauss, Linda

Sent: Tuesday, May 16, 2017 1:01 PM

To: Cleland-Hamnett, Wendy <Cleland-Hamnett.Wendy@epa.gov>; Wise, Louise <Wise.Louise@epa.gov>; Beck, Nancy <Beck.Nancy@epa.gov>; Schmit, Ryan <schmit.ryan@epa.gov>; Morris, Jeff <Morris.Jeff@epa.gov>; Pierce, Alison <Pierce.Alison@epa.gov>; Ng, Brian <Ng.Brian@epa.gov>

Subject: Pat asking for our good news story - FW: LINDA/: BNA - PAT - Reporter checking status of this request

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

From: Daguillard, Robert
Sent: Tuesday, May 16, 2017 10:53 AM
To: Strauss, Linda <Strauss.Linda@epa.gov>
Cc: Dunton, Cheryl <Dunton.Cheryl@epa.gov>
Subject: RE: LINDA/: BNA - PAT - Reporter checking status of this request

Ex. 5 - Deliberative Process

“Robert, I’m seeing there’s a “good news” story for EPA. The more I explore EPA’s various new

chemical websites today, the more I realize that the agency has posted a lot more information. I intend to write a short story today about more info. being available. It would be good for my readers and for EPA to let its voice be heard about what it's done. For today's story and, separately, for the special report.

Yes, I must write the story today, because EPA has made the new information available today.

I'd love to know how many new chemicals are still under review by the agency. I looks like dozens maybe hundreds have been cleared. That would be consistent with something I heard, which is that there are only about 200 new chemicals under review.

I'd love to know whether this is a sign that the agency is being able to review new chemicals more quickly than—apparently—it had been. Or perhaps the agency has been chugging along all the time, but couldn't say anything until all this was officially posted. I'd love to discuss on the questions I posed for my special report, but the main thing would be to talk to someone who can tell me authoritatively what's been newly posted. My gut says this is the info. folks have been waiting for; I've already got one comment to that effect, but I need to hear from EPA what it has done.”

I mean, does all this look remotely feasible today?

From: Strauss, Linda
Sent: Tuesday, May 16, 2017 10:44 AM
To: Daguillard, Robert <Daguillard.Robert@epa.gov>
Cc: Dunton, Cheryl <Dunton.Cheryl@epa.gov>
Subject: RE: LINDA/: BNA - PAT - Reporter checking status of this request

checking

From: Daguillard, Robert
Sent: Tuesday, May 16, 2017 10:42 AM
To: Strauss, Linda <Strauss.Linda@epa.gov>

Cc: Dunton, Cheryl <Dunton.Cheryl@epa.gov>
Subject: RE: LINDA/: BNA - PAT - Reporter checking status of this request

Good morning,

Follow-up from Pat: Do you want to discuss?

“I thought I might be able to delay my special report if Jeff Morris’ participation in our June 12 webinar was going to prevent an interview now, BUT I can’t do that. I’m to proceed with the special report on the status of, concerns about --- and hopefully information from EPA regarding--- the new chemicals program. That means I still need to have the interview this week as I said in the original request. Can you update me on status of my request? ”

From: Daguillard, Robert
Sent: Friday, May 12, 2017 10:52 AM
To: Strauss, Linda <Strauss.Linda@epa.gov>
Cc: Dunton, Cheryl <Dunton.Cheryl@epa.gov>
Subject: LINDA/: BNA - PAT - Reporter checking status of this request

Good morning Linda,

Pat from BNA has been ping about these questions and this interview request, which leads me to a couple of things:

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Thanks, in advance, R.

=====

I have two requests: 1st an interview with Wendy Cleland-Hamnet, Jeffrey Morris, or other appropriate senior OCSPP or OPPT official regarding the new chemicals program. The interview is for a special report giving me some flexibility as to when, but I would like to have the interview no later than May 22. It could be in person or by phone, although in person would be ideal.

2nd numerical figures about the status of PMN and MCAN reviews

I. Illustrative questions I need to ask an EPA official (*final questions may vary as I speak with more stakeholders prior to my interview with EPA*)

1) Do you think the number of PMNs, in particular, but also MCANs that are under review by OPPT's new chemicals program is a problem?

2) What health or environmental issues are raising questions as EPA reviews the new chemicals and how is that similar or different than prior to Lautenberg?

3) Prior to Lautenberg, I'm told the agency often tied data requests to production volume, for

example, it would let a chemical enter commerce but required data once production volume hit particular targets. Now, I'm told the EPA is more often wanting the data before the chemical is allowed to enter commerce. What's EPA's perspective?

4) I've heard industry speakers say Lautenberg codified new chemical review practices the agency already had. Is that an accurate description?

5) What are the questions raised by Lautenberg, requirements the EPA must meet or presumptions about new chemicals being made that are causing the logjam?

6) What solutions are you considering?

II. Figures about new chemicals program that I am seeking ahead of that interview

7) How many PMNs were under review as of April 30, 2017.

8) How many MCANS were under review as of April 30, 2017.

9) How many PMNs, and how many MCANS have been withdrawn since June 22, 2016 (i.e. since Lautenberg went into effect)?

10) How many PMNs and how many MCANS have been allowed to enter commerce since June 22, 2016? (I realize these are posted, and I recently counted 63, but I want to make sure I'm counting them correctly.)

11) How many action letters has EPA sent since June 22, 2016?

12) What's the range of study types—acute, chronic, dermal, multigene repro., etc.--that the agency has said it would like to receive?

Pat

Pat Rizzuto

Bloomberg BNA, Inc.